Research Report Screener Results

Report Screener | Stock Screener | Bond Screener | Fund Screener

Report Search Results As of 24-May-2013
New Screen

All Reports | Brokerage Reports | Independent Reports

All Reports (Showing 1 to 10 of 23)

Release
Date Contributor Author Title Pages Price StarMine Author Rating More Info

EPS Accuracy * Portfolio Return **
24-May-13 New Constructs, LLC N/A PIP: Due Diligence Review: Forensic Earnings and Valuation 13 $25 View Abstract
24-May-13 ValuEngine, Inc. N/A ValuEngine Industry Report for Medical-drugs 18 $207 View Abstract
23-May-13 Thomson Reuters Stock Report StockReports + Research Department Thomson Reuters Stock Report - PHARMATHENE INC NEW. (PIP-A) 11 $25 View Abstract
23-May-13 Thomson Reuters Stock Report StockReports + Research Department Thomson Reuters Stock Report - PEPSI-COLA PRODUCTS PHILIPPINES INC (PIP-PH) 11 $25 View Abstract
23-May-13 GlobalData GlobalData PharmAthene, Inc. (PIP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile 36 $250 View Abstract
21-May-13 Wright Reports N/A Wright Investors Service Comprehensive Report for Pepsi-Cola Products Philippines Inc 40 $460 View Abstract
18-May-13 Reuters Investment Profile N/A Pepsi Cola Products Philippines Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. 12 $138 View Abstract
18-May-13 Reuters Investment Profile N/A Pipe Works L Girakian Profil SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. 12 $138 View Abstract
18-May-13 Pechala's Reports Frantisek Pechala PHARMATHENE INC (PIP) 12-months forecast 1 $15 View Abstract
17-May-13 Reuters Investment Profile N/A PharmAthene Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. 12 $138 View Abstract
Next 13

Brokerage Reports (Showing 1 to 1 of 1)

Release
Date Contributor Author Title Pages Price StarMine Author Rating More Info

EPS Accuracy * Portfolio Return **
26-Apr-13 Maybank ATR Kim Eng Mr. Lovell Sarreal Maybank ATR Kim Eng Interim results: Pepsi-Cola Products Philippines Inc (PIP): Strong start for the year, beats Coke again (BUY) 7 $80.50 View Abstract

Independent Reports (Showing 1 to 10 of 22)

Release
Date Contributor Author Title Pages Price More Info
24-May-13 New Constructs, LLC N/A PIP: Due Diligence Review: Forensic Earnings and Valuation 13 $25 View Abstract
24-May-13 ValuEngine, Inc. N/A ValuEngine Industry Report for Medical-drugs 18 $207 View Abstract
23-May-13 Thomson Reuters Stock Report StockReports + Research Department Thomson Reuters Stock Report - PHARMATHENE INC NEW. (PIP-A) 11 $25 View Abstract
23-May-13 Thomson Reuters Stock Report StockReports + Research Department Thomson Reuters Stock Report - PEPSI-COLA PRODUCTS PHILIPPINES INC (PIP-PH) 11 $25 View Abstract
23-May-13 GlobalData GlobalData PharmAthene, Inc. (PIP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile 36 $250 View Abstract
21-May-13 Wright Reports N/A Wright Investors Service Comprehensive Report for Pepsi-Cola Products Philippines Inc 40 $460 View Abstract
18-May-13 Reuters Investment Profile N/A Pepsi Cola Products Philippines Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. 12 $138 View Abstract
18-May-13 Reuters Investment Profile N/A Pipe Works L Girakian Profil SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. 12 $138 View Abstract
18-May-13 Pechala's Reports Frantisek Pechala PHARMATHENE INC (PIP) 12-months forecast 1 $15 View Abstract
17-May-13 Reuters Investment Profile N/A PharmAthene Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. 12 $138 View Abstract
Next 12

* EPS Accuracy is a measure of an analyst's ability to accurately estimate the EPS for a company.
** Portfolio Return is a measure of the performance of an analyst's recommendations relative to his peers.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.